Based in East Brunswick, New Jersey, Avet is a rapid growth specialty pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic and legacy branded pharmaceutical products for the U.S. prescription drug market. Avet, formed in 2006, currently markets a variety of products in multiple pack sizes. Avet’s products cover a number of therapeutic categories, including but not limited to: cardiovascular, metabolic disease, anti-infective and pain management.
The Company’s business model utilizes a virtually integrated global supply network that leverages strategic outsourcing to US FDA approved manufacturing and development organizations in both North America and Asia. The Company owns a robust pipeline of multisource and high barrier products and will continue to introduce new generic products during the coming years as its pipeline matures through the regulatory approval cycle.
The foundation and advantage of our business model is the integration of a strong commercial operations and sales team with a global supply chain network that provides access to low cost development, materials and manufacturing capacity. Our network provides dedicated services for research and development and commercial manufacturing, with built in materials and manufacturing cost efficiencies. The advantage of Avet’s “virtual” business model is that it allows us to be efficient and flexible in business development while focusing on commercialization excellence and customer service.